Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 44 Pages
|Cervarix(人類乳突病毒(HPV)預防疫苗)- 預測與市場分析 Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 44 Pages||
The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.
Cervarix is manufactured and marketed by GSK, and consists of recombinant VLPs of the L1 capsid proteins from HPV strains 16 and 18, produced using a Baculovirus expression system. VLPs are combined with GSK's proprietary AS04 adjuvant, adsorbed on aluminum hydroxide. Cervarix is administered as a three-dose schedule with the second and third doses at one and six months following the first dose, respectively.